Effect of Long-Term Anti-Hypertensive β-Receptor-Blocking Treatment on Haemodynamic and Metabolic Responses to Prolonged Exercise in Man

1976 ◽  
Vol 51 (s3) ◽  
pp. 489s-491s
Author(s):  
M. Frisk-Holmberg ◽  
A. Juhlin-Dannfeldt ◽  
L. Jorfeldt ◽  
H. Åström
Keyword(s):  
Blood Flow ◽  
Prolonged Exercise ◽  
Plasma Concentrations ◽  
Receptor Blocking ◽  
Leg Blood Flow ◽  
Drug Plasma Concentrations ◽  
Drug Plasma ◽  
Long Term Treatment ◽  
Β Receptor

1. Central and regional haemodynamics and leg metabolism at rest, during and after a prolonged exercise were studied in seven untreated hypertensive males before and after a long-term treatment (6 weeks) with an unselective β-receptor-blocking drug (alprenolol). 2. Alprenolol treatment (200–400 mg, twice daily) decreased arterial blood pressure at rest and during exercise; it reduced heart rate in relation to drug plasma concentrations during and after exercise; it left cardiac output unchanged; it reduced leg blood flow at rest, but had no effect on leg blood flow during exercise. 3. Alprenolol treatment also decreased lipolysis and lactate release in relation to drug plasma concentrations during exercise.

scholarly journals Effects of long-term treatment with carvedilol on myocardial blood flow in idiopathic dilated cardiomyopathy

Heart ◽  
2007 ◽  
Vol 93 (7) ◽  
pp. 808-813 ◽  
Author(s):  
Danilo Neglia ◽  
Renata De Maria ◽  
Stefano Masi ◽  
Michela Gallopin ◽  
Patrizia Pisani ◽  
...  
Keyword(s):  
Blood Flow ◽  
Myocardial Blood Flow ◽  
Dilated Cardiomyopathy ◽  
Term Treatment ◽  
Idiopathic Dilated Cardiomyopathy ◽  
Long Term Treatment

Norepinephrine spillover from skeletal muscle during exercise in humans: role of muscle mass

1989 ◽  
Vol 257 (6) ◽  
pp. H1812-H1818 ◽  
Author(s):  
G. K. Savard ◽  
E. A. Richter ◽  
S. Strange ◽  
B. Kiens ◽  
N. J. Christensen ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Blood Flow ◽  
Muscle Mass ◽  
Nervous Activity ◽  
Plasma Concentrations ◽  
Whole Body ◽  
Knee Extensors ◽  
Sympathetic Nervous Activity ◽  
Leg Blood Flow ◽  
Sympathetic Nervous

The purpose of this study was to determine the effect of increasing muscle mass involvement in dynamic exercise on both sympathetic nervous activation and local hemodynamic variables of individual active and inactive skeletal muscle groups. Six male subjects performed 15-min bouts of one-legged knee extension either alone or in combination with the knee extensors of the other leg and/or with the arms. The range of work intensities varied between 24 and 71% (mean) of subjects' maximal aerobic capacity (% VO2max). Leg blood flow, measured in the femoral vein by thermodilution, was determined in both legs. Arterial and venous plasma concentrations of norepinephrine (NE) and epinephrine were analyzed, and the calculated NE spillover was used as an index of sympathetic nervous activity to the limb. NE spillover increased gradually both in the resting, and to a larger extent in the exercising legs, with a steeper rise occurring approximately 70% VO2max. These increases were not associated with any significant changes in leg blood flow or leg vascular conductance at the exercise intensities examined. These results suggest that, as the total active muscle mass increases, the rise in sympathetic nervous activity to skeletal muscle, either resting or working at a constant load, is not associated with any significant neurogenic vasoconstriction and reduction in flow or conductance through the muscle vascular bed, during whole body exercise demanding up to 71% VO2max.

Antiarrhythmic Drug Plasma Concentrations in Ambulatory Patients

1996 ◽  
Vol 30 (3) ◽  
pp. 298-300 ◽  
Author(s):  
Roberto Latini ◽  
Gianna Magnolfi ◽  
Rossella Zordan ◽  
Mariano Ferrari ◽  
Roberto Padrini ◽  
...  
Keyword(s):  
Antiarrhythmic Drug ◽  
Plasma Concentrations ◽  
Drug Plasma Concentrations ◽  
Drug Plasma ◽  
Ambulatory Patients

HIGH PLASMA CONCENTRATIONS OF β-RECEPTOR BLOCKING DRUGS AND DEFICIENT DEBRISOQUINE HYDROXYLATION

The Lancet ◽  
1982 ◽  
Vol 319 (8267) ◽  
pp. 333 ◽  
Author(s):  
Gunnar Alvan ◽  
Christer Von Bahr ◽  
Peter Seideman ◽  
Folke Sjöqvist
Keyword(s):  
Plasma Concentrations ◽  
High Plasma ◽  
Receptor Blocking ◽  
Β Receptor ◽  
Debrisoquine Hydroxylation

Long term treatment of moderate hypertension with the beta1-receptor blocking agent metoprolol

1977 ◽  
Vol 11 (4) ◽  
pp. 239-245 ◽  
Author(s):  
B. -G. Hansson ◽  
J. -F. Dymling ◽  
H. Hedeland ◽  
U. L. Hulth�n
Keyword(s):  
Moderate Hypertension ◽  
Blocking Agent ◽  
Term Treatment ◽  
Receptor Blocking ◽  
Long Term Treatment

Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 306-306
Author(s):  
Y. Kang ◽  
C. Yoo ◽  
B. Ryoo ◽  
H. Chang ◽  
J. Lee ◽  
...  
Keyword(s):  
Plasma Level ◽  
Gastrointestinal Stromal Tumors ◽  
Plasma Concentrations ◽  
Term Treatment ◽  
Albumin Concentration ◽  
Stromal Tumors ◽  
Long Term Treatment ◽  
The Mean ◽  
Median Interval

306 Background: Pharmacokinetic study in patients with gastrointestinal stromal tumors (GISTs) suggested that plasma concentrations of imatinib decrease following long-term exposure. We therefore measured changes in imatinib plasma trough levels (Cmin) after long-term exposure. Methods: Between November 2009 and May 2010, follow-up (FU) imatinib Cmin was measured in 65 patients who received the same dose of imatinib for at least 9 months after a previous baseline (BL) measurement. Total 244 blood samples were obtained (127 at BL and 117 at FU) and plasma level was measured by liquid chromatography-tandem mass spectrometry. Results: Median patient age was 54 years (range, 28–76 years) and 42 (64.6%) patients were male. Sixty-one (93.8%) patients were treated with 400 mg/day imatinib and 4 (6.2%) with 300 mg/day. The median interval from initiation of imatinib to BL test was 6.4 months (range, 0.5–66.6 months), and the median interval between BL and FU test was 13.1 months (range, 9.6–18.4 months). The mean ± standard deviation imatinib Cmin was significantly higher at FU than at BL (1442 ± 693 ng/mL vs 1221 ± 624 ng/mL, p<0.001). The mean inter- and intra-subject variabilities were 49.2% and 25.5%, respectively, at BL, and 44.2% and 20.4%, respectively, at FU. Multivariate analysis showed a significant correlation between the ratio of FU to BL imatinib Cmin and that of albumin (r=-0.397, p=0.001). In per-sample analysis, imatinib Cmin was significantly correlated with age, hemoglobin, albumin, creatinine clearance, previous major gastrectomy and time between initiation of imatinib and plasma level tests. Conclusions: Steady-state imatinib Cmin did not decrease but remained stable in most GIST patients during long-term treatment. Changes in imatinib Cmin were associated with changes in albumin concentration. Monitoring of imatinib Cmin only for concerns about time-dependent decreases in imatinib exposure is not necessary. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document